Cancer/testis antigen 2
Cancer/testis antigen 2 (108-120) is a synthetic peptide fragment derived from the immunodominant region of the cancer/testis antigen family, specifically encompassing amino acids 108 to 120 within the parent protein sequence. This peptide is of significant interest in the field of tumor immunology due to its restricted expression profile—being largely absent from normal somatic tissues except for the testis, yet frequently upregulated in a variety of malignancies. The unique expression pattern and antigenic properties make it a valuable tool for investigating tumor-associated immune responses, antigen processing, and presentation mechanisms. As a well-defined epitope, Cancer/testis antigen 2 (108-120) serves as a model system for exploring the fundamental aspects of peptide-MHC binding and T-cell recognition within oncological research.
Epitope mapping: The synthetic peptide corresponding to the 108-120 region of cancer/testis antigen 2 is commonly utilized in epitope mapping studies to define the specific amino acid sequences recognized by cytotoxic T lymphocytes (CTLs) in the context of cancer. By incorporating this fragment into immunoassays or T-cell activation experiments, researchers can delineate the minimal epitope necessary for immune recognition, supporting the identification of immunogenic domains relevant for tumor immunosurveillance. Such mapping is pivotal for advancing knowledge of tumor-specific immune responses and refining antigen selection in immunotherapeutic development.
Antigen presentation research: Cancer/testis antigen 2 (108-120) is frequently employed in studies investigating the molecular mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) molecules. Its defined sequence enables controlled examination of peptide loading onto MHC class I or II molecules, facilitating analysis of peptide stability, affinity, and the efficiency of presentation to T cells. These insights are crucial for understanding how tumor antigens are displayed to the immune system and for optimizing peptide-based immunological assays.
T-cell activation assays: The 108-120 peptide fragment is instrumental in functional assays designed to evaluate T-cell responses, including proliferation, cytokine release, and cytotoxic activity. By pulsing antigen-presenting cells with this peptide, investigators can assess the specificity and magnitude of T-cell activation in vitro. Such assays are essential for characterizing antigen-specific T-cell populations, monitoring immune responses in preclinical studies, and validating the immunogenicity of candidate epitopes.
Peptide-MHC binding studies: Researchers utilize the defined sequence of Cancer/testis antigen 2 (108-120) in quantitative binding assays to determine its affinity for various MHC alleles. These studies provide valuable data on the peptide's binding kinetics, stability, and potential cross-reactivity with different MHC molecules. The results inform the selection of optimal peptide candidates for downstream immunological applications and contribute to a deeper understanding of the structural determinants governing peptide-MHC interactions.
Peptide synthesis and analytical validation: The Cancer/testis antigen 2 (108-120) peptide serves as an important reference standard in peptide synthesis and analytical method development. Its well-characterized sequence and physicochemical properties make it suitable for validating synthetic protocols, optimizing purification strategies, and calibrating analytical techniques such as high-performance liquid chromatography (HPLC) or mass spectrometry. Accurate synthesis and validation of this peptide are essential for ensuring experimental reproducibility and reliability in a wide range of immunological and biochemical assays.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More